Menu
Search
|

Menu

Close
X

Obalon Therapeutics Inc OBLN.OQ (NASDAQ Stock Exchange Global Market)

1.91 USD
-- (--)
As of Jul 21
chart
Previous Close 1.91
Open --
Volume --
3m Avg Volume 25,374
Today’s High --
Today’s Low --
52 Week High 10.35
52 Week Low 1.85
Shares Outstanding (mil) 16.82
Market Capitalization (mil) 169.25
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
10
FY16
3
FY15
1
EPS (USD)
FY18
-0.714
FY17
-2.078
FY16
-1.244
FY15
-0.223
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
33.99
5.73
Price to Book (MRQ)
vs sector
3.37
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
19.71
16.84
LT Debt to Equity (MRQ)
vs sector
19.71
12.51
Return on Investment (TTM)
vs sector
-75.69
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Kim Kamdar
Chairman of the Board, Since 2008
Salary: --
Bonus: --
Andrew Rasdal
President, Chief Executive Officer, Director, Since 2008
Salary: $400,000.00
Bonus: $100,000.00
William Plovanic
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Kelly Huang
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Nooshin Hussainy
Vice President - Finance, Since 2011
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

5421 Avenida Encinas Ste F
CARLSBAD   CA   92008-4410

Phone: +1858.4802400

Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

SPONSORED STORIES